Cellectar biosciences announces closing of up to approximately $103 million private placement financing

Florham park, n.j., sept. 11, 2023 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that it has closed on its previously announced private placement with certain institutional investors that is expected to result in gross proceeds of up to $102.9 million, including gross proceeds of $24.5 million which the company received at closing. the financing was led by rosalind advisors with participation from aigh capital, adar1, second line, nantahala capital, augc, and other new and existing institutional investors.
CLRB Ratings Summary
CLRB Quant Ranking